6 minute read
Jul. 7, 2023

Why is the pan-KRAS inhibitor, BI-2493, a big deal? 

BI-2493

oral reversible pan-KRAS inhibitor oral activity in xenograft models (10-90 mpk BID) from prior covalent KRAS G12C inhibitor Nature, May 31, 2023 Boehringer Ingelheim, Vienna, AT

twitterlinkedinprintemail

MOTY Nominees

Molecule of the Year